Antengene Corporation Limited reported revenue of RMB 53.2 million for the six months ended June 30, 2025, a decrease from RMB 60.8 million in the same period last year. The company posted a net loss of RMB 76.4 million for the period, compared to a net loss of RMB 167.0 million in the corresponding period of 2024. Gross profit for the first half of 2025 was RMB 42.9 million, down from RMB 51.9 million in the previous year. Research and development costs declined to RMB 79.9 million from RMB 130.8 million, and selling and distribution expenses decreased to RMB 37.0 million from RMB 56.0 million for the same period last year. Administrative expenses also dropped to RMB 39.3 million, compared to RMB 58.5 million in the first half of 2024. Other income and gains increased to RMB 38.1 million from RMB 27.3 million, mainly due to a rise in government grants. The company highlighted that its research and development costs and selling and distribution expenses were significantly lower, reflecting decreased drug development expenses, R&D employee costs, and distribution spending. No updates regarding changes to the company's operational strategy or major business developments were included in the report.